Skin biopsy utilization and melanoma incidence among Medicare beneficiaries

M. A. Weinstock, J. P. Lott, Q. Wang, L. J. Titus, T. Onega, Heidi Nelson, L. Pearson, M. Piepkorn, R. L. Barnhill, J. G. Elmore, A. N.A. Tosteson

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: Melanoma incidence has increased in recent decades in the U.S.A. Uncertainty remains regarding how much of this increase is attributable to greater melanoma screening activities, potential detection bias and overdiagnosis. Objectives: To use a cross-sectional ecological analysis to evaluate the relationship between skin biopsy and melanoma incidence rates over a more recent time period than prior reports. Methods: Examination of the association of biopsy rates and melanoma incidence (invasive and in situ) in SEER-Medicare data (including 10 states) for 2002–2009. Results: The skin biopsy rate increased by approximately 50% (6% per year) throughout this 8-year period, from 7012 biopsies per 100 000 persons in 2002 to 10 528 biopsies per 100 000 persons in 2009. The overall melanoma incidence rate increased approximately 4% (< 1% per year) over the same time period. The incidence of melanoma in situ increased approximately 10% (1% per year), while the incidence of invasive melanoma increased from 2002 to 2005 then decreased from 2006 to 2009. Regression models estimated that, on average, for every 1000 skin biopsies performed, an additional 5·2 (95% confidence interval 4·1–6·3) cases of melanoma in situ were diagnosed and 8·1 (95% confidence interval 6·7–9·5) cases of invasive melanoma were diagnosed. When considering individual states, some demonstrated a positive association between biopsy rate and invasive melanoma incidence, others an inverse association, and still others a more complex pattern. Conclusions: Increased skin biopsies over time are associated with increased diagnosis of in situ melanoma, but the association with invasive melanoma is more complex.

Original languageEnglish (US)
Pages (from-to)949-954
Number of pages6
JournalBritish Journal of Dermatology
Volume176
Issue number4
DOIs
StatePublished - Apr 1 2017

Fingerprint

Medicare
Melanoma
Biopsy
Skin
Incidence
Confidence Intervals
Uncertainty
Cross-Sectional Studies

ASJC Scopus subject areas

  • Dermatology

Cite this

Weinstock, M. A., Lott, J. P., Wang, Q., Titus, L. J., Onega, T., Nelson, H., ... Tosteson, A. N. A. (2017). Skin biopsy utilization and melanoma incidence among Medicare beneficiaries. British Journal of Dermatology, 176(4), 949-954. https://doi.org/10.1111/bjd.15077

Skin biopsy utilization and melanoma incidence among Medicare beneficiaries. / Weinstock, M. A.; Lott, J. P.; Wang, Q.; Titus, L. J.; Onega, T.; Nelson, Heidi; Pearson, L.; Piepkorn, M.; Barnhill, R. L.; Elmore, J. G.; Tosteson, A. N.A.

In: British Journal of Dermatology, Vol. 176, No. 4, 01.04.2017, p. 949-954.

Research output: Contribution to journalArticle

Weinstock, MA, Lott, JP, Wang, Q, Titus, LJ, Onega, T, Nelson, H, Pearson, L, Piepkorn, M, Barnhill, RL, Elmore, JG & Tosteson, ANA 2017, 'Skin biopsy utilization and melanoma incidence among Medicare beneficiaries', British Journal of Dermatology, vol. 176, no. 4, pp. 949-954. https://doi.org/10.1111/bjd.15077
Weinstock, M. A. ; Lott, J. P. ; Wang, Q. ; Titus, L. J. ; Onega, T. ; Nelson, Heidi ; Pearson, L. ; Piepkorn, M. ; Barnhill, R. L. ; Elmore, J. G. ; Tosteson, A. N.A. / Skin biopsy utilization and melanoma incidence among Medicare beneficiaries. In: British Journal of Dermatology. 2017 ; Vol. 176, No. 4. pp. 949-954.
@article{6b17600536d84171b55d175ece05e9d4,
title = "Skin biopsy utilization and melanoma incidence among Medicare beneficiaries",
abstract = "Background: Melanoma incidence has increased in recent decades in the U.S.A. Uncertainty remains regarding how much of this increase is attributable to greater melanoma screening activities, potential detection bias and overdiagnosis. Objectives: To use a cross-sectional ecological analysis to evaluate the relationship between skin biopsy and melanoma incidence rates over a more recent time period than prior reports. Methods: Examination of the association of biopsy rates and melanoma incidence (invasive and in situ) in SEER-Medicare data (including 10 states) for 2002–2009. Results: The skin biopsy rate increased by approximately 50{\%} (6{\%} per year) throughout this 8-year period, from 7012 biopsies per 100 000 persons in 2002 to 10 528 biopsies per 100 000 persons in 2009. The overall melanoma incidence rate increased approximately 4{\%} (< 1{\%} per year) over the same time period. The incidence of melanoma in situ increased approximately 10{\%} (1{\%} per year), while the incidence of invasive melanoma increased from 2002 to 2005 then decreased from 2006 to 2009. Regression models estimated that, on average, for every 1000 skin biopsies performed, an additional 5·2 (95{\%} confidence interval 4·1–6·3) cases of melanoma in situ were diagnosed and 8·1 (95{\%} confidence interval 6·7–9·5) cases of invasive melanoma were diagnosed. When considering individual states, some demonstrated a positive association between biopsy rate and invasive melanoma incidence, others an inverse association, and still others a more complex pattern. Conclusions: Increased skin biopsies over time are associated with increased diagnosis of in situ melanoma, but the association with invasive melanoma is more complex.",
author = "Weinstock, {M. A.} and Lott, {J. P.} and Q. Wang and Titus, {L. J.} and T. Onega and Heidi Nelson and L. Pearson and M. Piepkorn and Barnhill, {R. L.} and Elmore, {J. G.} and Tosteson, {A. N.A.}",
year = "2017",
month = "4",
day = "1",
doi = "10.1111/bjd.15077",
language = "English (US)",
volume = "176",
pages = "949--954",
journal = "British Journal of Dermatology",
issn = "0007-0963",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Skin biopsy utilization and melanoma incidence among Medicare beneficiaries

AU - Weinstock, M. A.

AU - Lott, J. P.

AU - Wang, Q.

AU - Titus, L. J.

AU - Onega, T.

AU - Nelson, Heidi

AU - Pearson, L.

AU - Piepkorn, M.

AU - Barnhill, R. L.

AU - Elmore, J. G.

AU - Tosteson, A. N.A.

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Background: Melanoma incidence has increased in recent decades in the U.S.A. Uncertainty remains regarding how much of this increase is attributable to greater melanoma screening activities, potential detection bias and overdiagnosis. Objectives: To use a cross-sectional ecological analysis to evaluate the relationship between skin biopsy and melanoma incidence rates over a more recent time period than prior reports. Methods: Examination of the association of biopsy rates and melanoma incidence (invasive and in situ) in SEER-Medicare data (including 10 states) for 2002–2009. Results: The skin biopsy rate increased by approximately 50% (6% per year) throughout this 8-year period, from 7012 biopsies per 100 000 persons in 2002 to 10 528 biopsies per 100 000 persons in 2009. The overall melanoma incidence rate increased approximately 4% (< 1% per year) over the same time period. The incidence of melanoma in situ increased approximately 10% (1% per year), while the incidence of invasive melanoma increased from 2002 to 2005 then decreased from 2006 to 2009. Regression models estimated that, on average, for every 1000 skin biopsies performed, an additional 5·2 (95% confidence interval 4·1–6·3) cases of melanoma in situ were diagnosed and 8·1 (95% confidence interval 6·7–9·5) cases of invasive melanoma were diagnosed. When considering individual states, some demonstrated a positive association between biopsy rate and invasive melanoma incidence, others an inverse association, and still others a more complex pattern. Conclusions: Increased skin biopsies over time are associated with increased diagnosis of in situ melanoma, but the association with invasive melanoma is more complex.

AB - Background: Melanoma incidence has increased in recent decades in the U.S.A. Uncertainty remains regarding how much of this increase is attributable to greater melanoma screening activities, potential detection bias and overdiagnosis. Objectives: To use a cross-sectional ecological analysis to evaluate the relationship between skin biopsy and melanoma incidence rates over a more recent time period than prior reports. Methods: Examination of the association of biopsy rates and melanoma incidence (invasive and in situ) in SEER-Medicare data (including 10 states) for 2002–2009. Results: The skin biopsy rate increased by approximately 50% (6% per year) throughout this 8-year period, from 7012 biopsies per 100 000 persons in 2002 to 10 528 biopsies per 100 000 persons in 2009. The overall melanoma incidence rate increased approximately 4% (< 1% per year) over the same time period. The incidence of melanoma in situ increased approximately 10% (1% per year), while the incidence of invasive melanoma increased from 2002 to 2005 then decreased from 2006 to 2009. Regression models estimated that, on average, for every 1000 skin biopsies performed, an additional 5·2 (95% confidence interval 4·1–6·3) cases of melanoma in situ were diagnosed and 8·1 (95% confidence interval 6·7–9·5) cases of invasive melanoma were diagnosed. When considering individual states, some demonstrated a positive association between biopsy rate and invasive melanoma incidence, others an inverse association, and still others a more complex pattern. Conclusions: Increased skin biopsies over time are associated with increased diagnosis of in situ melanoma, but the association with invasive melanoma is more complex.

UR - http://www.scopus.com/inward/record.url?scp=85014119091&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014119091&partnerID=8YFLogxK

U2 - 10.1111/bjd.15077

DO - 10.1111/bjd.15077

M3 - Article

VL - 176

SP - 949

EP - 954

JO - British Journal of Dermatology

JF - British Journal of Dermatology

SN - 0007-0963

IS - 4

ER -